JP2024517945A5 - - Google Patents
Info
- Publication number
- JP2024517945A5 JP2024517945A5 JP2023569958A JP2023569958A JP2024517945A5 JP 2024517945 A5 JP2024517945 A5 JP 2024517945A5 JP 2023569958 A JP2023569958 A JP 2023569958A JP 2023569958 A JP2023569958 A JP 2023569958A JP 2024517945 A5 JP2024517945 A5 JP 2024517945A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- alkoxy
- leukemia
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163188704P | 2021-05-14 | 2021-05-14 | |
| US63/188,704 | 2021-05-14 | ||
| PCT/US2022/029271 WO2022241265A1 (en) | 2021-05-14 | 2022-05-13 | Inhibitors of the menin-mll interaction |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024517945A JP2024517945A (ja) | 2024-04-23 |
| JP2024517945A5 true JP2024517945A5 (https=) | 2025-05-19 |
Family
ID=84029448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023569958A Pending JP2024517945A (ja) | 2021-05-14 | 2022-05-13 | メニン－ｍｌｌ相互作用の阻害剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US11919901B2 (https=) |
| EP (1) | EP4337203A4 (https=) |
| JP (1) | JP2024517945A (https=) |
| KR (1) | KR20240047338A (https=) |
| CN (1) | CN117956992A (https=) |
| AR (1) | AR125866A1 (https=) |
| AU (1) | AU2022274325A1 (https=) |
| BR (1) | BR112023023463A2 (https=) |
| CA (1) | CA3213074A1 (https=) |
| CL (1) | CL2023003327A1 (https=) |
| IL (1) | IL308476A (https=) |
| MX (1) | MX2023013515A (https=) |
| TW (1) | TW202311262A (https=) |
| WO (1) | WO2022241265A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017214367A1 (en) | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| IL308476A (en) | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| AR130379A1 (es) * | 2022-09-02 | 2024-12-04 | Hutchmed Ltd | Compuestos de triazina y usos de los mismos |
| CN120529900A (zh) | 2022-11-24 | 2025-08-22 | 奥莱松基因组股份有限公司 | 用于治疗癌症的LSD1抑制剂和Menin抑制剂的组合 |
| WO2025106901A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination cancer therapies with a kras modulator and an rtk-mapk pathway inhibitor |
| WO2025106905A1 (en) * | 2023-11-17 | 2025-05-22 | Quanta Therapeutics, Inc. | Combination therapies with a kras modulator and an immunomodulator inhibitor |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5820915A (en) | 1996-06-27 | 1998-10-13 | Bioavailability Systems, L.L.C. | Method for the preparation of a first-pass effective citrus-derived substance and product thereof |
| US6124477A (en) | 1996-06-27 | 2000-09-26 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5990154A (en) | 1997-05-30 | 1999-11-23 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds and citrus extract |
| US20040058982A1 (en) | 1999-02-17 | 2004-03-25 | Bioavailability System, Llc | Pharmaceutical compositions |
| US6248776B1 (en) | 1997-08-26 | 2001-06-19 | Bioavailability Systems, L.L.C. | Anti-first-pass effect compounds |
| US6063809A (en) | 1997-08-26 | 2000-05-16 | Bioavailability Systems, Llc | Anti-first-pass effect compounds |
| US5993887A (en) | 1998-06-29 | 1999-11-30 | Bioavailability Systems, L.L.C. | Safe citrus juice and process for preparation |
| WO2004037827A1 (en) | 2000-10-20 | 2004-05-06 | Bioavailability Systems, Llc | Synthesis of spiro ortho esters, spiro ortho carbonates, and intermediates |
| JP2007528423A (ja) | 2004-03-11 | 2007-10-11 | セコイア、ファーマシューティカルズ、インコーポレイテッド | 耐性防止レトロウイルスプロテアーゼ阻害薬 |
| US7378441B2 (en) | 2004-05-07 | 2008-05-27 | Sequoia Pharmaceuticals, Inc. | Resistance-repellent retroviral protease inhibitors |
| US20090281114A1 (en) | 2008-05-08 | 2009-11-12 | Fabre-Kramer Pharmaceuticals, Inc. | Indolylalkyl derivatives of pyrimidinylpiperazine and metabolites thereof for treatment of anxiety, depression, and sexual dysfunction |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| MX354412B (es) | 2011-06-10 | 2018-03-05 | Merck Patent Gmbh | Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton. |
| US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
| WO2014164543A1 (en) | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| US11596636B2 (en) | 2014-01-14 | 2023-03-07 | The Trustees Of The University Of Pennsylvania | Tailored combinatorial epigenetic therapies for P53 gain-of-function tumors |
| US20170119769A1 (en) | 2014-06-10 | 2017-05-04 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| AU2015301746A1 (en) | 2014-08-13 | 2017-02-16 | Celgene Corporation | Combination therapy for treating cancer |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| AU2016378579A1 (en) | 2015-12-22 | 2018-06-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-MLL interaction |
| US10869868B2 (en) | 2016-01-26 | 2020-12-22 | Memorial Sloan Kettering Cancer Center | Targeting chromatin regulators inhibits leukemogenic gene expression in NPM1 mutant leukemia |
| PH12018501955B1 (en) | 2016-03-16 | 2024-01-24 | Kura Oncology Inc | Bridged bicyclic inhibitors of menin-mll and methods of use |
| ES2990061T3 (es) | 2016-05-10 | 2024-11-28 | C4 Therapeutics Inc | Degronímeros espirocíclicos para la degradación de proteínas diana |
| WO2017214367A1 (en) * | 2016-06-10 | 2017-12-14 | Vitae Pharmaceuticals, Inc. | Inhibitors of the menin-mll interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| JP7307729B2 (ja) | 2017-12-20 | 2023-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤 |
| JP7060694B2 (ja) | 2018-01-18 | 2022-04-26 | アレイ バイオファーマ インコーポレイテッド | Ｒｅｔキナーゼ阻害剤としての置換ピロロ［２，３－ｄ］ピリミジン化合物 |
| EP3774731A4 (en) | 2018-03-30 | 2021-11-24 | The Regents Of The University Of Michigan | PIPERIDINE COMPOUNDS AS COVALENT MENINE INHIBITORS |
| KR102779601B1 (ko) * | 2018-08-27 | 2025-03-12 | 스미토모 파마 가부시키가이샤 | 광학 활성인 아자비시클로환 유도체 |
| AU2019337547A1 (en) | 2018-09-13 | 2021-03-18 | Merck Sharp & Dohme Llc | Combination of PD-1 antagonist and LAG3 antagonist for treating non-microsatellite instablity-high/proficient mismatch repair colorectal cancer |
| JP2022503792A (ja) | 2018-09-26 | 2022-01-12 | クラ オンコロジー，インク． | メニン阻害剤を用いた血液悪性腫瘍の処置 |
| SG11202106304RA (en) | 2018-12-31 | 2021-07-29 | Biomea Fusion Llc | Irreversible inhibitors of menin-mll interaction |
| EP4132932A4 (en) | 2020-04-07 | 2024-04-17 | Syndax Pharmaceuticals, Inc. | COMBINATIONS OF MENIN INHIBITORS AND CYP3A4 INHIBITORS AND METHODS OF USE THEREOF |
| IL308476A (en) * | 2021-05-14 | 2024-01-01 | Syndax Pharmaceuticals Inc | Inhibitors of the menin-mil interaction |
| TW202320796A (zh) | 2021-08-11 | 2023-06-01 | 美商拜歐米富士恩股份有限公司 | 用於糖尿病的menin-mll相互作用之共價抑制劑 |
| US20250295661A1 (en) * | 2022-05-09 | 2025-09-25 | Syndax Pharmaceuticals, Inc. | Menin-mll inhibitors for the treatment of cancer |
-
2022
- 2022-05-13 IL IL308476A patent/IL308476A/en unknown
- 2022-05-13 MX MX2023013515A patent/MX2023013515A/es unknown
- 2022-05-13 US US17/744,249 patent/US11919901B2/en active Active
- 2022-05-13 TW TW111118095A patent/TW202311262A/zh unknown
- 2022-05-13 US US18/289,970 patent/US20240400564A1/en active Pending
- 2022-05-13 WO PCT/US2022/029271 patent/WO2022241265A1/en not_active Ceased
- 2022-05-13 KR KR1020237043336A patent/KR20240047338A/ko active Pending
- 2022-05-13 EP EP22808443.0A patent/EP4337203A4/en active Pending
- 2022-05-13 AR ARP220101276A patent/AR125866A1/es unknown
- 2022-05-13 CA CA3213074A patent/CA3213074A1/en active Pending
- 2022-05-13 CN CN202280034670.8A patent/CN117956992A/zh active Pending
- 2022-05-13 AU AU2022274325A patent/AU2022274325A1/en active Pending
- 2022-05-13 BR BR112023023463A patent/BR112023023463A2/pt unknown
- 2022-05-13 JP JP2023569958A patent/JP2024517945A/ja active Pending
-
2023
- 2023-11-08 CL CL2023003327A patent/CL2023003327A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024517945A5 (https=) | ||
| JP5046922B2 (ja) | 少なくとも一つのピロロベンゾジアゼピン誘導体とフルダラビンとを含有する治療用組成物 | |
| SI2809657T1 (en) | New therapeutic agents | |
| ATE383360T1 (de) | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs | |
| CA2605738A1 (en) | Novel azaheterocyclic compounds as kinase inhibitors | |
| KR20220035955A (ko) | Sting 작용제로서의 거대고리 화합물 및 이의 방법 및 용도 | |
| CA2653941A1 (en) | Substituted amino purine derivatives and uses thereof | |
| JP2020507606A5 (https=) | ||
| JP2022525216A5 (ja) | 癌の治療のための免疫調節薬の組み合わせ | |
| RU2019138222A (ru) | Применение ингибитора ezh2 в комбинации с ингибитором btk в получении лекарственного средства для лечения опухоли | |
| KR20210002015A (ko) | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 | |
| RU2011134283A (ru) | Имидазотиазольные производные, имеющие пролиновую циклическую структуру | |
| JP2024050668A (ja) | がんの治療方法 | |
| JP2021523169A5 (https=) | ||
| IL274919B1 (en) | Albumin-binding prodrugs of auristatin E derivatives | |
| CN105611928A (zh) | Pim激酶抑制剂组合 | |
| JP2020529418A5 (ja) | Ｔ細胞急性リンパ芽球性白血病を治療するための化合物、組成物及び方法 | |
| JP2009543874A5 (https=) | ||
| RU2007141398A (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ИЗОИНДОЛОВ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ИХ, ИХ ПОЛУЧЕНИЕ И ФАРМАЦЕВТИЧЕСКОЕ ПРИМЕНЕНИЕ, В ЧАСТНОСТИ, В КАЧЕСТВЕ ИНГИБИТОРОВ АКТИВНОСТИ БЕЛКА-ШАПЕРОНА Hsp90 | |
| FOYE et al. | Cyclophosphamide: A preliminary study of a new alkylating agent | |
| JP2006515854A5 (https=) | ||
| JP2014177487A (ja) | 慢性リンパ性白血病の処置のためのニロチニブとナイトロジェンマスタードの組み合わせ剤 | |
| JP2005531563A5 (https=) | ||
| CA2523253A1 (en) | Methyl indoles and methyl pyrrolopyridines as alpha-1 adrenergic agonists | |
| CZ301053B6 (cs) | Farmaceutický prostredek a farmaceutické výrobky |